Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | STAT1 | P42224 | 1/20 | 0.36 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3138158 | 0.96 | MAOA (0.38) | MAOAMAOBCYP2A6PRKCIHSD17B10 | |
| SCHEMBL15844709 | 0.86 | — | — | |
| SCHEMBL8194619 | 0.86 | MAOA (0.33) | MAOAMAOBCYP2A6PRKCIHSD17B10 | |
| SCHEMBL10198693 | 0.74 | — | — | |
| SCHEMBL13315856 | 0.70 | PTPRC (0.32) | PTPRC | |
| SCHEMBL22606205 | 0.69 | HPGD (0.43) | HSD17B10NPSR1HTTPKMMEN1 | |
| SCHEMBL3227687 | 0.67 | — | — | |
| SCHEMBL23804865 | 0.66 | HTR2A (0.42) | MAOAMAOBCYP2A6PRKCIHSD17B10 | |
| SCHEMBL22606096 | 0.65 | ALDH1A1 (0.38) | MAOAHSD17B10NPSR1SMN1; SMN2HTT | |
| SCHEMBL22606094 | 0.65 | SLC6A2 (0.32) | MAOAMAOBKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400501-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2024-12-05 | — | — | US | disclosed |
| US-20240131356-A1 | COMBINATION OF INTRACELLULAR AND EXTRACELLULAR PHOTOSENSITIZERS FOR TREATMENT OF BACTERIAL INFECTION | VANDERBILT UNIVERSITY | 2024-04-25 | — | — | US | disclosed |
| EP-4284912-A1 | COMBINATION OF INTRACELLULAR AND EXTRACELLULAR PHOTOSENSITIZERS FOR TREATMENT OF BACTERIAL INFECTION | Vanderbilt University (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20220402866-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220402866-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2022-12-22 | — | — | US | disclosed |
| WO-2022165023-A1 | COMBINATION OF INTRACELLULAR AND EXTRACELLULAR PHOTOSENSITIZERS FOR TREATMENT OF BACTERIAL INFECTION | VANDERBILT UNIVERSITY (US) | 2022-08-04 | — | — | WO | disclosed |
| EP-3998256-A1 | CRYSTALLINE FORM OF CXCR2 ANTAGONIST AND APPLICATION THEREOF | Shenzhen Optimum Biological Technology Co., Ltd (CN) | 2022-05-18 | — | — | EP | disclosed |
| US-11208377-B2 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | ALLERGAN, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11208377-B2 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | ALLERGAN, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11136315-B2 | CXCR2 antagonist | MEDSHINE DISCOVERY INC. (CN) | 2021-10-05 | — | — | US | disclosed |
| US-20130068993-A1 | DEICER COMPOSITIONS AND PROCESSES FOR MAKING DEICERS | API INTELLECTUAL PROPERTY HOLDINGS, LLC (US) | 2013-03-21 | — | — | US | disclosed |
| US-20110306595-A1 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2011-12-15 | — | — | US | disclosed |
| US-20110306595-A1 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2011-12-15 | — | — | US | disclosed |
| WO-2010094242-A1 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. (US) | 2010-08-26 | — | — | WO | disclosed |
| US-5834499-A | TREATING GASTROINTESTINAL DISORDERS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1998-11-10 | — | — | US | disclosed |
| US-5604224-A | NEURODEGENERATIVE DISORDERS | STERLING WINTHROP INC. (US) | 1997-02-18 | — | — | US | disclosed |
| EP-0749966-A1 | 5-HT 3 RECEPTOR AGONIST, NOVEL THIAZOLE DERIVATIVE, AND INTERMEDIATE THEREFOR | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1996-12-27 | — | — | EP | disclosed |
| US-5569655-A | Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof | STERLING WINTHROP INC. (US) | 1996-10-29 | — | — | US | disclosed |
| EP-0647641-A1 | Substituted heterocyclylisoquinolinium salts and compositions and methods of usethereof | STERLING WINTHROP INC. (US) | 1995-04-12 | — | — | EP | disclosed |
| US-5304554-A | Intercalators of DNA, inhibit replication of retroviruses | EMORY UNIVERSITY (US) | 1994-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400501-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | IL17A, TSLP, SSB | MAOA 3698/4885MAOB 1695/4885CYP2A6 432/4885 |
| US-11208377-B2 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | IL17A, TSLP, SSB | MAOA 3698/4885MAOB 1695/4885CYP2A6 432/4885 |
| US-20220402866-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | IL17A, TSLP, SSB | MAOA 3698/4885MAOB 1695/4885CYP2A6 432/4885 |
| US-20110306595-A1 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, APP | MAOA 865/4885MAOB 740/4885CYP2A6 909/4885 |
| US-11136315-B2 | CXCR2 antagonist | CXCR2, CXCR3, CXCR1 | MAOA 4772/4885MAOB 4331/4885CYP2A6 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.